This document summarizes several research studies on various antibiotics and antimicrobial agents. It discusses penicillin and its derivatives as immune response triggers. It also looks at hypersensitivity reactions to beta-lactam antibiotics in children and methods of synthesis and molecular modeling of cephalosporins. Additional articles summarize the pH potential of antimicrobials under environmental and light factors, glycopeptides in clinical development, targeting the bacterial cell wall, mechanisms of antimicrobial resistance, and dalbavancin origin and activity. Further articles address tigecycline, fluoroquinolones, tuberculosis treatment, rifaximin, shortening treatment for tuberculosis, polymyxin B sulfate, colistin, mechanisms of newer antibiotics

1.  Alpízar Olivares Yulién. (2010). La penicilina y sus derivados como agentes desencadenantes de la respuesta inmune. Revista Cubana Hematol
Inmunol Hemoter, 16(2) , 99.104
 M Blanca, MJ Torres, (2012). Reacciones de hipersensibilidad a antibióticos Beta-lactámicos en la infancia. Revista allergologia el Immunopathologia. 31(3), 4-10

2.  Zalua Rodríguez-Riera, Blanca Idelmis Tolón-Murguía y Miguel Antonio López-López. (2010). Cefalosporinas: métodos de síntesis y estudios de modelación molecular. Revista CENIC Ciencias Químicas. 41(3). 177- 182.

3.  Renata Maria Coelho Crepaldi; Cíntia Monteiro; Maria Angélica Sorgini Peterlini; Mavilde da Luz Gonçalves Pedreira. (2010). Potencial hidrogenionico de antimicrobianos, según los factores ambientales y luminosidad. Revista latino – americano Enfermage. 18(2).60-70.

4.  Van Bambeke F. (2012). Glycopeptides in clinical development:pharmocological profile and clinical perspectives. Curr OpiPharmacol. 59.471  Stein GE, Craig WA. (2013). Tigecycline a critical analysis. Clin Infect Dis. 43. 518-524.
 Silver LL.(2011) Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? Biochem Pharmacol. 71:996-1005.
 Page MGP. (2010) Anti-MRSA β-lactamantibiotics. Curr Opin Pharmacol. 6: 480-5.
 Tenover FC.(2013) Mechanisms of antimicrobial resistance in bacteria. Am J Med.119:S3-10.
 Malabarba A, Goldstein BP. (2013) Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 55 Suppl S2:15- 20.
 Craig WA. (2013) Basic pharmacodynamics of antibacterial with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 17:479-502.
 Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A.(2011) High- dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infection. Efficacy and toxicity. Arch Intern Med. 166:2138- 44.
 Hermann T. (2010) Drug targeting the ribosome. Curr Opi Str Biol. 15:355-66.
 Tenson T, Mankin A.(2010) Antibiotics and the ribosome. Mol Microbiol. 59:1664-77.
 Stein GE, Craig WA.(2011) Tigecycline: a critical analysis. Clin Infect Dis. 43:518-24.
 Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. (2013) A critical review of the fluoroquinolones. Focus on respiratory tract infections. Drugs.62:13-59.
 Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al; American Thoracic Society, Centers for Disea- se Control and Prevention and the Infectious Diseases Society. (2013) Treatment of tuberculosis. Am J Respir Crit Care Med. 167:603- 62.
 Scarpgnato C, Pelosini I. (2011) Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 51 Suppl 1:33-66.
 Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O’Brien RJ, et al. (2014) Moxifloxacin-containing regimens of reduced du- ration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 170:1131-4.

5.  Evans ME, Feola DJ, Rapp RP. (2010) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacol. 33:960-7.
 Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al.(2010) Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 6:589-601.
 Hancock REW.(2010) Mechanisms of action of newer antibiotics for gram-positive organisms. Lancet Infect Dis. 5:209-18.
 Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J.(2011) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clini- cal impact. J Infect Dis. 191(2)149-52.
 Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al; (2011) S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 355: 653-65.